# A targeted protein degrader shows promise against arthritis in mice

> Researchers used AI-guided single-cell analysis to find an enzyme in rheumatoid-arthritis joint-lining cells, then built a targeted degrader that eased arthritis in mice — still preclinical, not a human treatment.

_Source: Advanced Science research article, checked against PubMed PMID 42671010, Crossref, PMC full text PMC13528181, and the originating Telegram post · 2026-09-14 · 5 min read · Verified against primary sources_

Canonical: https://iyu.app/e/rheumatoid-arthritis-ogt-protac

## The 60-second version

AI-guided single-cell analysis identified OGT in rheumatoid-arthritis joint-lining cells, and an FLS-targeted PROTAC reduced arthritis severity in mice — a preclinical proof of concept, not a human treatment.

**Key points**

- OGT was found enriched in aggressive fibroblast-like synoviocytes from RA synovium using AI-based single-cell transcriptomics.
- In vitro, OGT drove FLS invasiveness; FLS-specific OGT knockout in mice reduced joint swelling and erosion.
- The team built a nucleolin-targeted PROTAC that degrades OGT selectively in those cells and attenuated arthritis in mice.
- All results are from cells and mice; human efficacy, safety and dosing are unproven.

**Verdict.** Promising research pathway with a clear mechanism, but it does not change rheumatoid arthritis treatment today.

## Full explainer

> **⚑ Caveat:** 所有治疗性结论都来自细胞实验和关节炎小鼠模型。该PROTAC尚未在人体中测试，不是可用药物，也不改变现有类风湿关节炎标准治疗。


### What the study did — AI found an enzyme inside joint-lining cells

Researchers applied AI-based single-cell analysis (scTransMIL plus SCimilarity) to synovial tissue data and identified **OGT** — an enzyme that adds O-GlcNAc sugar modifications to proteins — as highly enriched in the fibroblast-like synoviocytes (FLS) that drive rheumatoid arthritis.


### The biology check — Turning OGT off reduced the aggressive cell state

In lab experiments, activating OGT made FLS more invasive; silencing it reversed that. Deleting OGT specifically in FLS of arthritic mice reduced joint swelling, synovial overgrowth, and bone and cartilage erosion. Mechanistically, OGT stabilizes the protein SAP130, which leads to silencing of the growth-suppressor gene BTG2.


### The therapeutic idea — A targeted degrader instead of a blunt inhibitor

The team built a **PROTAC** that destroys OGT: an OGT-inhibitor piece (OSMI-1) joined to an aptamer (AS1411) that homes to nucleolin on the surface of pathogenic FLS. In mice, systemic delivery eased arthritis, and adding the TNF inhibitor etanercept showed added benefit.

- **Study design:** AI-guided target discovery, in vitro gain/loss-of-function, FLS-specific knockout, and PROTAC treatment in mouse arthritis models.
- **Evidence level:** Preclinical only: human cells and mice; no human trials.
- **Main findings:** OGT enriched in RA-FLS; OGT-SAP130-BTG2 axis drives FLS aggressiveness; FLS-targeted PROTAC attenuates arthritis in mice.
- **Combination:** PROTAC plus etanercept showed additive benefit in mice.

- **0.5–1%** — of adults affected by rheumatoid arthritis (per the paper)
- **25–40%** — of patients without adequate response to current drugs (per the paper)
- **Preclinical** — cells and mice only — no human data

> The notable part is the pipeline: AI-driven discovery of a stromal enzyme, mechanism first, then a cell-type-specific degradation strategy.


### What it does not mean — Not a treatment yet

There is no human efficacy, safety, or dosing data. The molecule is experimental, and the study does not change current care for rheumatoid arthritis. The honest reading is a proof of concept for targeting the stromal side of the disease.


## Primary sources

- [Originating Telegram post 1480](https://t.me/CNSmydream/1480)
- [Advanced Science paper, DOI 10.1002/advs.77466](https://doi.org/10.1002/advs.77466)
- [PubMed PMID 42671010](https://pubmed.ncbi.nlm.nih.gov/42671010/)
- [PMC full text PMC13528181](https://pmc.ncbi.nlm.nih.gov/articles/PMC13528181/)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._